Periodontal Regeneration by application ofParticulate Dentin Graft (PDG) with Recombinant Human Platelet-Derived Growth Factor (RHPDGF) in human periodontal infrabony defects: An In-Vivo and In-VitroEvaluation

开始日期2022-07-18

申办/合作机构

Indian Council of Medical Research

100 项与 PDGF (Curis) 相关的临床结果

登录后查看更多信息

100 项与 PDGF (Curis) 相关的转化医学

登录后查看更多信息

100 项与 PDGF (Curis) 相关的专利（医药）

登录后查看更多信息

项与 PDGF (Curis) 相关的文献（医药）

2021-01-01·Journal of Applied Biomaterials & Functional Materials4区 · 工程技术

Guided bone regeneration with osteoconductive grafts and PDGF: A tissue engineering option for segmental bone defect reconstruction

4区 · 工程技术

Article

作者: Badwelan, Mohammed ; Ramalingam, Sundar ; Alghamdi, Osama ; Alkindi, Mohammed ; Alomran, Omar Mohamed ; Binsalah, Mohammed Awadh

Regeneration and reconstruction of segmental bone defects (SBD) is a clinical challenge in maxillofacial surgery and orthopedics. The present study evaluated efficacy of guided bone-regeneration (GBR) of rat femoral SBD using osteoconductive equine-bone (EB) and beta-tricalcium phosphate (beta-TCP) grafts, either with or without platelet-derived growth-factor (PDGF). Following ethical-approval, 50 male Wistar-Albino rats (aged ~12–15 months and weighing ~450–500 g) were included. A 5 mm femoral critical-size SBD was created and animals were divided into five groups depending on the graft material used for GBR (EB, EB + PDGF, Autograft, beta-TCP, beta-TCP + PDGF; n = 10/group). Following 12-weeks of healing, animals were sacrificed and femur specimens were analyzed through qualitative histology and quantitative histomorphometry. There was new bone bridging femoral SBD in all groups and qualitatively, better bone formation was seen in autograft and EB + PDGF groups. Histomorphometric bone-area (BA %) was significantly high in autograft group, followed by EB + PDGF, beta-TCP + PDGF, EB, and beta-TCP groups. Addition of PDGF to EB and beta-TCP during GBR resulted in significantly higher BA%. After 12-weeks of healing, EB + PDGF for GBR of rat femoral segmental defects resulted in new bone formation similar to that of autograft. Based on this study, GBR with EB and adjunct PDGF could be a potential clinical alternative for reconstruction and regeneration of segmental bone defects.

2020-10-09·ACS Infectious Diseases2区 · 医学

Codelivery of Sustainable Antimicrobial Agents and Platelet-Derived Growth Factor via Biodegradable Nanofibers for Repair of Diabetic Infectious Wounds

2区 · 医学

Article

作者: Fu, Xuebin ; Liu, Kuo-Sheng ; Cheng, Che-Wei ; Wen, Ming-Shien ; Chang, Shang-Hung ; Lee, Chen-Hung ; Hsieh, I-Chang ; Hung, Kuo-Chun ; Liu, Shih-Jung ; Chan, Err-Cheng ; Juang, Jyuhn-Huarng ; Hsieh, Ming-Jer

More than half of diabetic wounds demonstrate clinical signs of infection at presentation and lead to poor outcomes. This work develops coaxial sheath-core nanofibrous poly(lactide-co-glycolide) (PLGA) scaffolds that are loaded with bioactive antibiotics and platelet-derived growth factor (PDGF) for the repair of diabetic infectious wounds. PDGF and PLGA/antibiotic solutions were pumped, respectively, into two independent capillary tubings for coaxial electrospinning to prepare biodegradable sheath-core nanofibers. Spun nanofibrous scaffolds sustainably released PDGF, vancomycin, and gentamicin for 3 weeks. The scaffolds also reduced the phosphatase and tensin homologue content, enhanced the amount of angiogenesis marker (CD31) around the wound area, and accelerated healing in the early stage of infected diabetic wound repair. Antibiotic/biomolecule-loaded PLGA nanofibers may provide a very effective way to aid tissue regeneration at the sites of infected diabetic wounds.

2020-03-01·Journal of Oral and Maxillofacial Surgery4区 · 医学

Multiple Treatment Meta-Analysis of Intra-Articular Injection for Temporomandibular Osteoarthritis

4区 · 医学

Review

作者: Wu, Jia-Shun ; Fei, Wei ; Tang, Ya-Ling ; Liang, Xin-Hua ; Tang, Ya-Jie ; Liu, Yan

PURPOSEThe purpose of the present study was to compare the efficacy of intra-articular injections of different agents for temporomandibular osteoarthritis (TMJOA) using a network meta-analysis.MATERIALS AND METHODSA comprehensive search strategy was performed in multiple English and Chinese language electronic databases. Randomized controlled trials comparing the effect of intra-articular injections of different agents to treat TMJOA were included in accordance with the inclusion and exclusion criteria. The bias of risk in each study was assessed, with data extraction performed independently by 2 reviewers. The primary outcomes included pain intensity and maximal mouth opening.RESULTSA total of 11 trials were included in the present study, and 10 different agents (ie, hyaluronic acid, dexamethasone, prednisolone, betamethasone, betamethasone plus hyaluronic acid, morphine, tramadol, platelet-derived growth factor [PDGF], placebo, arthrocentesis alone) administered using intra-articular injections were assessed. The evidence from the direct comparisons showed that arthrocentesis plus sodium hyaluronate resulted in significantly better pain relief outcomes compared with arthrocentesis alone. Also, the visual analog scale score was further reduced to 1.27 by PDGF injection after arthrocentesis (arthrocentesis plus PDGF) compared with arthrocentesis alone. Morphine and tramadol had a high probability of being the best treatment for pain control, with PDGF ranked third. When considering pain relief, arthrocentesis plus sodium hyaluronate resulted in a better outcome than arthrocentesis alone, and arthrocentesis plus PDGF was better than arthrocentesis plus placebo. PDGF injections had the greatest probability of being the best treatment for improving joint opening, followed by sodium hyaluronate.CONCLUSIONSTramadol, morphine, and PDGF injections after arthrocentesis were effective in the treatment of TMJOA with excellent effects in reducing pain and improving joint opening. Hyaluronic acid injections were effective for improving the maximal mouth opening of patients with TMJOA in the short-term. The combination of a corticosteroid and hyaluronic acid injection reduced the symptoms of TMJOA more than corticosteroid injections alone, but not of hyaluronic acid alone.

项与 PDGF (Curis) 相关的新闻（医药）

2024-05-01

·药融圈

迁总部，国资加持：新药biotech，申报港股(含招股书PPT)

▲5月30-31日第八届广州生物医药创新者峰会扫码立即报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。大环境与医药融资态势虽然没有恢复，但是不耽误咱们做事儿！药融云数据www.pharnexcloud.com监测显示：2024年4月29日，总部在山东青岛的华芢生物科技(青岛)股份有限公司（以下简称“华芢生物”）在中国香港港交所递交IPO招股书，拟主板上市。华芢生物最早在2012年于北京成立。药融云数据www.pharnexcloud.com截至2024年4月22日，华芢生物的管线包括10款候选产品，其中有7款重组人血小板衍生生长因子（PDGF）候选产品（此外还有mRNA疫苗在研），覆盖广泛的创面愈合适应症，包括烧烫伤、糖足、新鲜创面、压疮、放射性溃疡、干眼症、角膜损伤、日旋光性皮炎、脱发、痔疮及胃溃疡。候选产品当中包括2款核心产品Pro-101-1和Pro-101-2，是重组人血小板衍生生长因子-BB(rhPDGF–BB)药物。Pro-101-1，是中国治疗烧烫伤临床开发进度最快的PDGF候选药物，有望成为中国首款用于该适应症的商业化的PDGF产品。华芢生物已于2023年12月在中国进入Pro- 101-1治疗烧烫伤的IIb期临床试验，预期将于2025年第二季度完成试验，拟于2025年第三季度启动III期临床试验，并于2026年第四季度完成试验，计划于2027年在中国推出该产品。华芢生物亦于2021年12月就Pro-101-1治疗烧烫伤向FDA提交了IND前沟通申请，FDA同意公司开展临床试验的建议及通过创新生物制剂审批途径提交Pro-101-1治疗烧烫伤的BLA。公司预期将于2026年第一季度向FDA提交IND申请。Pro-101-2，令公司有望成为在中国率先实现治疗糖尿病足溃疡(糖足)的PDGF药物商业化的领先生物制药公司之一。I期临床结果表明，Pro-101-2在治疗糖足方面具有良好的安全性和耐受性。华芢生物于2022年2月在中国进入Pro-101-2治疗糖足的II期临床试验。此后，公司已进行新产品规格注册，并对现有临床试验方案进行若干修订。公司预期于2027 年第二季度完成II期临床试验，拟于2027年第三季度启动III期临床试验并于2029年第二季度完成试验，计划于2030年于中国推出该产品。2022年和2023年，华芢生物营收分别为0元和47.2万元人民币；研发开支分别为3481.8万和3991.5万元人民币；相应期间的净亏损分别为0.86亿和1.05亿元人民币。2021年10月，华芢生物宣布顺利完成亿元A轮融资。本轮融资由鼎晖投资独家投资，公司投后估值20.21亿元人民币。2023年4月，北京华芢生物技术有限公司与青岛崂山区签署合作协议，落地华芢生物总部项目，建设包括TPG凝胶在内的一类新药研发、生产、销售、办公总部基地。2023年5月24日，北京华芢生物技术有限公司与青岛高科产业发展有限公司签署战略投资合作协议，本轮公司投后估值超33亿人民币。附，分享：华芢生物的第一次IPO招股书PPT/PDF公开。发送IPO（请正确复制）至药融圈微信公众号（点击下方发送）后台可获得原文件。仅供学习交流分享！参考：NMPA/CDE；药融云数据www.pharnexcloud.com；FDA/EMA/PMDA；相关公司公开披露；https://www1.hkexnews.hk/app/sehk/2024/106430/documents/sehk24042905317_c.pdf；等等。本文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场，不作任何用药推荐活动推荐点击图片查看详情↓↓【关于药融圈】药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。

疫苗临床3期IPO临床2期信使RNA

100 项与 PDGF (Curis) 相关的药物交易

登录后查看更多信息